New drug hope for kids with rare Muscle-Weakening disease

NCT ID NCT06149559

Ongoing Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and researchers monitor side effects and changes in antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rozanolixizumab
What this could lead to: If it works, this could provide a new treatment option for children with generalized myasthenia gravis, helping control muscle weakness and improve daily life.
What could go wrong: This is a small, early-phase study with only 12 participants, so results may not apply to all children. The drug may cause serious side effects like infections or headaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Mg0006 20339

Ōbu, Japan
Mg0006 20340

Fuchu-shi, Japan
Mg0006 20343

Sagamihara, Japan
Mg0006 40144

Milan, Italy
Mg0006 40155

Warsaw, Poland
Mg0006 40290

Bologna, Italy
Mg0006 40733

Naples, Italy
Mg0006 40734

Lodz, Poland
Mg0006 40841

Yenimahalle, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.